End Treatment Response in Chronic Hepatitis C Patients to Sofosbuvir and Ribavirin

Objective: To investigate the end treatment response of Sofosbuvir and Ribavirin in chronic hepatitis C patients and determine the efficacy of this drug combination. Study Design: Retrospective study Place and Duration: September 15th 2015 and May 19th 2016 Materials and Methods: A total of 153 cases were taken who attended the hospital between September 15th 2015 and May 19th 2016 were included in this study and had their PCR done at 4 and 24 months. It comprises of both treatment naive (those who had not been treated previously for Hepatitis C) and treatment experienced (those who had previous treatment failure for hepatitis C or relapse, either due to the drug intolerance, drug resistance and/or other factors). SPSS v21 was used to analyze the data. Results: The end treatment response with aforementioned combination was calculated for 153 cases in which 96.07% responded to the therapy irrespective of their genotypes, type 3 being the most encountered in this study. There was no difference in treatment responses between males and females and p value came out .05 Conclusion: Drug Combination’s(Sofosbuvir and Ribavirin) efficacy was demonstrated in chronic hepatitis C patients. It was seen to be a very effective combination for the treatment compared to older regimens. Although this requires further studies to confirm the findings our study emphasize that this therapy should be made readily available.